Today's Research Reports on ProMIS Neurosciences, Resverlogix, Spectral Medical and Fennec Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
ProMIS Neurosciences Inc.
https://rdinvesting.com/news/?ticker=PMN.TO
Resverlogix Corp.
https://rdinvesting.com/news/?ticker=RVX.TO
Spectral Medical Inc.
https://rdinvesting.com/news/?ticker=EDT.TO
Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO
ProMIS Neurosciences' stock moved 2.00% lower Monday, to close the day at $0.24. The stock recorded a trading volume of 75,750 shares, which was below its three months average volume of 193,838 shares. In the last year, ProMIS Neurosciences shares have traded in a range of 0.10 - 0.35. The share price has gained 133.33% from its 52 week low. The company's shares are currently trading at their 200-day moving average. Moreover, the stock's 50-day moving average of $0.24 is below its 200-day moving average of $0.24. Shares of ProMIS Neurosciences have gained approximately 53.12 percent year-to-date.
Access RDI’s ProMIS Neurosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PMN.TO
On Monday, shares in Resverlogix recorded a trading volume of 19,504 shares, which was below the three months average volume of 59,508 shares. The stock ended the day 2.08% lower at 1.41. The stock is currently trading 42.91% below its 52-week high with a 52-week trading range of 1.23 - 2.47.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.37 is below its 200-day moving average of $1.76. Shares of Resverlogix have fallen approximately 17.06 percent year-to-date.
Access RDI's Resverlogix Corp. Research Report at:
https://rdinvesting.com/news/?ticker=RVX.TO
Spectral Medical's stock had no change Monday, to close the day at $0.37. The stock recorded a trading volume of 69,108 shares, which was above its three months average volume of 53,802 shares. In the last year, Spectral Medical's shares have traded in a range of 0.18 - 2.07. The share price has gained 105.56% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.38 is below its 200-day moving average of $0.44. Shares of Spectral Medical have gained approximately 34.55 percent year-to-date.
Access RDI's Spectral Medical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EDT.TO
On Monday, shares in Fennec Pharmaceuticals recorded a trading volume of 8,405 shares, which was above the three months average volume of 6,533 shares. The stock ended the day 8.77% lower at 13.00. The share price has gained 488.24% from its 52-week low with a 52-week trading range of 2.21 - 16.23.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $9.21 is greater than its 200-day moving average of $6.37. Shares of Fennec Pharmaceuticals have gained approximately 398.08 percent year-to-date.
Access RDI’s Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO
Our Actionable Research on ProMIS Neurosciences Inc. (TSX:PMN.TO), Resverlogix Corp. (TSX:RVX.TO), Spectral Medical Inc. (TSX:EDT.TO) and Fennec Pharmaceuticals Inc. (TSX:FRX.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
